Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
5
Neutral
6
Bullish
3
Bearish
33
Neutral
6
Bullish
7
Bearish
28
Neutral
0
Bullish
4
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Blue Jet Healthcare is a Mumbai‑headquartered specialty pharmaceutical and CDMO company manufacturing contrast media intermediates, high‑intensity sweeteners (saccharin and salts) and pharma intermediates/APIs, operating multiple regulatory‑accredited facilities and providing development, process research, and contract manufacturing solutions to global innovators and generic players.
Q3 FY26 reported revenue of Rs.1,924 mn with EBITDA of Rs.469 mn (24% margin) and PAT of Rs.402 mn, while 9M FY26 revenue is Rs.7,127 mn with EBITDA margin of 31% and PAT margin of 26%; recent quarter saw sharp YoY decline driven by customer de‑stocking and product mix shifts but nine‑month performance remains resilient.
Company is executing a large, multi‑year capex agenda including a board‑approved Rs.1,000 crore Vizag greenfield project, near‑completion of a Mahad backward‑integration block and an expanded R&D lease in Hyderabad, signalling strategic vertical integration and CDMO pipeline enablement that materially alters scale and capability for Blue Jet Healthcare.
Blue Jet’s competitive edge rests on complex chemistry capabilities, ~70% contracted sales, long tenures with top contrast media manufacturers, regulatory accreditations and targeted forward integration into advanced intermediates, providing Blue Jet Healthcare with sticky client relationships and differentiated margin potential in high barrier segments.
Operational and margin volatility in recent quarters has been influenced by customer de‑stocking, one‑time inventory write‑offs and engagement of foreign consultants; management expects normalization over a couple of quarters while pursuing sustainability targets (70% renewables) and award recognition for energy management at Blue Jet Healthcare.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
6,511 Cr
High Risk
0.3
28.0
—
5.2
1,028.20
352.75
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stockBlue Jet Healthcare Ltd (BLUEJET) is currently trading at 385.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Blue Jet Healthcare is a Mumbai‑headquartered specialty pharmaceutical and CDMO company manufacturing contrast media intermediates, high‑intensity sweeteners (saccharin and salts) and pharma intermediates/APIs, operating multiple regulatory‑accredited facilities and providing development, process research, and contract manufacturing solutions to global innovators and generic players. Q3 FY26 reported revenue of Rs.1,924 mn with EBITDA of Rs.469 mn (24% margin) and PAT of Rs.402 mn, while 9M FY26 revenue is Rs.7,127 mn with EBITDA margin of 31% and PAT margin of 26%; recent quarter saw sharp YoY decline driven by customer de‑stocking and product mix shifts but nine‑month performance remains resilient. Company is executing a large, multi‑year capex agenda including a board‑approved Rs.1,000 crore Vizag greenfield project, near‑completion of a Mahad backward‑integration block and an expanded R&D lease in Hyderabad, signalling strategic vertical integration and CDMO pipeline enablement that materially alters scale and capability for Blue Jet Healthcare. Blue Jet’s competitive edge rests on complex chemistry capabilities, ~70% contracted sales, long tenures with top contrast media manufacturers, regulatory accreditations and targeted forward integration into advanced intermediates, providing Blue Jet Healthcare with sticky client relationships and differentiated margin potential in high barrier segments. Operational and margin volatility in recent quarters has been influenced by customer de‑stocking, one‑time inventory write‑offs and engagement of foreign consultants; management expects normalization over a couple of quarters while pursuing sustainability targets (70% renewables) and award recognition for energy management at Blue Jet Healthcare.
Over the past 52 weeks, Blue Jet Healthcare Ltd has traded between a low of ₹352.75 and a high of ₹1,028.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Blue Jet Healthcare Ltd has a market capitalization of approximately 6,511.02. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Blue Jet Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 0.28 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 6,511.02 Cr, Blue Jet Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Blue Jet Healthcare Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Blue Jet Healthcare Ltd is 0.28. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
853.20 | 7,667 Cr | 15.38 | 2.78 | 0.48 | 14.42 | 14.96 | 8.14 | |
484.85 | 7,361 Cr | 23.33 | 2.34 | 0.00 | 10.07 | 8.99 | 6.29 | |
583.00 | 6,592 Cr | 45.58 | 8.03 | 0.00 | 20.63 | 23.80 | 17.20 | |
385.00 | 6,511 Cr | 0.28 | 5.19 | 0.32 | 28.06 | 37.35 | 19.22 | |
698.00 | 6,150 Cr | 29.62 | 3.01 | 0.74 | 11.72 | 12.99 | 6.54 | |
367.00 | 6,085 Cr | 27.55 | 2.50 | 1.34 | 9.27 | 12.51 | 7.51 | |
625.90 | 4,985 Cr | 27.15 | 4.61 | 0.16 | 16.86 | 22.47 | 15.40 |
